Successful Use of Vincristine in a Quarter Horse Gelding with Immune-Mediated Thrombocytopenia.

Overview

• This research article presents a case study of a 15-year-old Quarter Horse gelding successfully treated for presumed immune-mediated thrombocytopenia (IMTP) using vincristine.
• The horse showed severe thrombocytopenia and skin petechiae during hospitalization, and after various immunosuppressive treatments, vincristine helped restore normal platelet levels.

Introduction to Immune-Mediated Thrombocytopenia (IMTP)

• IMTP is a condition where the immune system attacks and destroys platelets, leading to low platelet counts (thrombocytopenia) and increased bleeding risk.
• It is uncommon in horses but more frequently documented and treated in small animals like dogs and cats.

Case Background and Clinical Presentation

• The patient was a 15-year-old Quarter Horse gelding admitted for a pinch skin graft surgery on the left forelimb.
• On day 10 of hospitalization, the horse developed:
  • Fever (102.6°F; reference interval 99-101°F)
  • Severe petechiae (small red or purple spots caused by bleeding under the skin) on mucous membranes
• A complete blood count (CBC) showed severe thrombocytopenia with platelet count at 16,000/μL (normal range 100,000-400,000/μL).

Diagnostic Testing and Exclusion of Other Causes

• Various diagnostic tests were performed to rule out infectious diseases known to cause thrombocytopenia:
  • Polymerase chain reaction (PCR) for Anaplasma phagocytophilum: negative
  • Competitive ELISA (cELISA) for Theileria equi and Babesia caballi: negative
  • Agar gel immunodiffusion test for equine infectious anemia (EIA) virus: negative
• Sternal bone marrow aspirate was performed to evaluate platelet precursor cells (megakaryocytes) but sample quality was poor, though it suggested megakaryocyte hypoplasia (decreased production).
• No evidence of consumptive disorders like disseminated intravascular coagulation (DIC) or chronic bleeding lesions was found.

Treatment and Response

• The horse was treated over a 20-day period with multiple immunosuppressive drugs to reduce immune destruction of platelets:
  • Dexamethasone (a corticosteroid)
  • Prednisolone (another corticosteroid)
  • Azathioprine (an immunosuppressive agent)
• Vincristine was administered as an additional therapy aimed at improving thrombopoiesis (platelet production).
• Following vincristine treatment, the platelet count increased substantially and eventually normalized, indicating a successful response.

Mechanism of Action of Vincristine

• Vincristine is a chemotherapeutic drug that, in the context of IMTP, is proposed to:
  • Stimulate thrombopoiesis by increasing fragmentation of megakaryocytes (platelet precursors) within the bone marrow
  • Lead to increased release of platelets into the bloodstream
• This effect helps replenish low platelet counts despite immune-mediated destruction.

Significance and Novelty

• This case represents one of the very few documented uses of vincristine successfully treating IMTP in horses, a treatment more commonly described in domestic small animals.
• The findings provide veterinary practitioners with an additional therapeutic option for managing immune-mediated thrombocytopenia in equines.
• By ruling out infectious causes and confirming platelet count recovery after vincristine, the authors support a presumptive diagnosis of IMTP in this horse.

Conclusion

• The case report highlights vincristine as a potentially effective treatment for IMTP in horses, expanding on existing knowledge primarily derived from small animal medicine.
• Further studies could validate vincristine’s role and optimize treatment protocols for equine patients with immune-mediated platelet disorders.